Table of Content


List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Primary Hyperoxaluria - Overview
Primary Hyperoxaluria - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Products under Development by Companies
Primary Hyperoxaluria - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Primary Hyperoxaluria - Companies Involved in Therapeutics Development
Alle Pharmaceuticals Inc
Alnylam Pharmaceuticals Inc
Amar Therapeutics BV
BridgeBio Pharma Inc
Dicer Pharmaceuticals Inc
Intellia Therapeutics Inc
OxThera AB
Precision Biosciences Inc
Primary Hyperoxaluria - Drug Profiles
AMA-001 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BBP-711 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
DCR-PHXC - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Gene Therapy to Inhibit HAO1 for Primary Hyperaxuluria - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Gene Therapy to Inhibit HAO1 for Primary Hyperoxaluria Type I - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
lumasiran - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Oxabact - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
reloxaliase - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Primary Hyperoxaluria - Dormant Projects
Primary Hyperoxaluria - Discontinued Products
Primary Hyperoxaluria - Product Development Milestones
Featured News & Press Releases
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer



List of Figures


Figure 1: Number of Products under Development for Primary Hyperoxaluria, H2 2019
Figure 2: Number of Products under Development by Companies, H2 2019
Figure 3: Number of Products by Targets, H2 2019
Figure 4: Number of Products by Stage and Targets, H2 2019
Figure 5: Number of Products by Mechanism of Actions, H2 2019
Figure 6: Number of Products by Stage and Mechanism of Actions, H2 2019
Figure 7: Number of Products by Routes of Administration, H2 2019
Figure 8: Number of Products by Stage and Routes of Administration, H2 2019
Figure 9: Number of Products by Molecule Types, H2 2019
Figure 10: Number of Products by Stage and Molecule Types, H2 2019


List of Tables


Table 1: Number of Products under Development for Primary Hyperoxaluria, H2 2019
Table 2: Number of Products under Development by Companies, H2 2019
Table 3: Products under Development by Companies, H2 2019
Table 4: Number of Products by Stage and Target, H2 2019
Table 5: Number of Products by Stage and Mechanism of Action, H2 2019
Table 6: Number of Products by Stage and Route of Administration, H2 2019
Table 7: Number of Products by Stage and Molecule Type, H2 2019
Table 8: Primary Hyperoxaluria - Pipeline by Allena Pharmaceuticals Inc, H2 2019
Table 9: Primary Hyperoxaluria - Pipeline by Alnylam Pharmaceuticals Inc, H2 2019
Table 10: Primary Hyperoxaluria - Pipeline by Amarna Therapeutics BV, H2 2019
Table 11: Primary Hyperoxaluria - Pipeline by BridgeBio Pharma Inc, H2 2019
Table 12: Primary Hyperoxaluria - Pipeline by Dicerna Pharmaceuticals Inc, H2 2019
Table 13: Primary Hyperoxaluria - Pipeline by Intellia Therapeutics Inc, H2 2019
Table 14: Primary Hyperoxaluria - Pipeline by OxThera AB, H2 2019
Table 15: Primary Hyperoxaluria - Pipeline by Precision Biosciences Inc, H2 2019
Table 16: Primary Hyperoxaluria - Dormant Projects, H2 2019
Table 17: Primary Hyperoxaluria - Discontinued Products, H2 2019